Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
तुलना करने के लिए मीट्रिक्स | NUVL | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNUVLपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −17.9x | −4.9x | −0.5x | |
PEG अनुपात | 0.37 | 0.21 | 0.00 | |
क़ीमत/बुक | 6.1x | 5.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 18.3x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 44.2% | 70.9% | 55.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.3% | 8.6% | अनलॉक करें |